Use of Virtual Reality Medical Hypnosis for Anxiolytic Purposes During Frozen Embryo Transfer (Hypno-TEC)

June 7, 2024 updated by: Hospices Civils de Lyon

Use of Virtual Reality Medical Hypnosis for Anxiolytic Purposes During Frozen Embryo Transfer - Hypno-TEC Feasibility Study

Assisted Reproduction Technology (ART) procedures are often long and particularly stressful for couples. The level of anxiety appears to persist throughout the entire process, particularly during embryo transfer, a pivotal and delicate stage in In Vitro Fertilization (IVF). Many women apprehend this maneuver, firstly, as it represents the culmination of the process and consequently elicits apprehensions regarding negative outcome, and secondly, as it instigates anxiety related to potential discomfort during the procedure.

Medical Hypnosis in Virtual Reality is a combination of hypnotherapy and immersion in a fictitious world, used in the medical field for anxiolytic and analgesic purposes. This fusion is made possible by a virtual reality headset coupled with an auditory device.

The diversion and relaxation conferred by this device can lead to a reduction in perceived anxiety and an indirect enhancement of compliance and cooperation during medical procedure. Several studies have already demonstrated a benefit on pre-operative and peri-operative anxiety, with reassuring safety data on the use of this medical device.

However, despite the common use of VRH in the medical field, encouraging data on anxiety reduction, and accessibility to these headsets within in certain ART departments, they are not routinely employed during embryo transfers. Various barriers to the implementation of this medical device in this indication seem to be present, encompassing organizational, technical, and practical aspects.

Consequently, the Hypno-TEC study aims to assess the feasibility of using virtual reality hypnosis (VRH) headset for anxiolytic purposes during frozen embryo transfer (FET).

Hypno-TEC will be a prospective interventional study, not comparative, and conducted at a single center, within the Reproductive Medicine Department of the Mother-Child-Woman Hospital in Lyon. This clinical investigation will fall under category 4.2 of medical device regulations, according to European Regulation 2017/745.

The enrolled patients, estimated to be 50 in number, will benefit from the device (VRH headset) during the execution of the FET procedure.

Besides assessing the feasibility of this usage, secondary outcomes will include: (i) evaluating the procedure's acceptability, (ii) patient and caregiver satisfaction with this application, (iii) effect on patient anxiety, and (iv) the pregnancy rates following the transfers concerned by the study.

The expected benefit is the potential to incorporate these headsets into routine practice, thereby would be enhancing patient adherence and tolerance to the transfer procedure.

Study Overview

Study Type

Interventional

Enrollment (Actual)

50

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Rhône
      • Bron, Rhône, France, 69500
        • Hôpital Femme Mère Enfant

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Female patient aged between 18 and 45
  • Currently undergoing In Vitro Fertilization treatment at the Assisted Reproduction Unit of the Mother-Child-Woman Hospital in Lyon
  • Having a frozen embryo transfer planned, and for which the companion plans to be present
  • Having signed an informed consent form
  • Affiliated with the French social security system
  • Understanding the French language, both spoken and written

Exclusion Criteria:

  • Unbalanced epilepsy
  • Patients with psychiatric disorders documented in their medical records
  • Visual impairments preventing use of virtual reality (lack of binocular vision)
  • Hearing impairments preventing use of audio headset (deafness, blindness)
  • Claustrophobia
  • First embryo transfer
  • Fresh embryo transfer
  • Persons under guardianship, curatorship or judicial protection
  • Individuals deprived of liberty, persons receiving psychiatric care, and individuals admitted to a health or social facility for purposes other than clinical investigation
  • Any medical condition judged by the investigator's expertise as incompatible with the research

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Other
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Other: Patients benefiting from the virtual reality hypnosis headset during frozen embryo transfer

The study will involve women, aged between 18 and 45, receiving care within the Reproductive Medicine Department at the Mother-Child-Woman Hospital in Lyon, as part of an assisted reproduction journey, and for whom a frozen embryo transfer is planned. The patients should have previously undergone an embryo transfer to be familiar with the medical procedure to be performed. Their partner must have planned to be present during the FET, in order to comply to identity vigilance regulations.

The study will be proposed to them during the consultation scheduled for the dispensing of their prescriptions in preparation for the transfer. If the patient agrees to participate, she will then use a virtual reality hypnosis headset during her frozen embryo transfer.

The virtual reality hypnosis headset will be used before, during, and after the FET procedure:

  • The headset will be put on 5 minutes prior to the procedure, allowing time for immersion in the virtual world.
  • The headset will be kept on throughout the entire procedure (procedure duration less than 5 minutes).
  • The headset will be worn for up to 5 minutes after the procedure. The patient will be free to choose her own auditory and visual scenario for the session.

Prior to the procedure and the device setup, the patient will be asked to complete a self-assessment anxiety questionnaire, the State-Trait Anxiety Inventory. This self-assessment questionnaire is a validated and standardized tool designed to measure temporary "state" anxiety related to a specific situation (in this case, the embryo transfer). After the procedure, the patient will need to complete the questionnaire again, along with another set of questions specifically designed for our study.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
The feasibility of using a virtual reality hypnosis headset for anxiolysis during a frozen embryo transfer
Time Frame: The composite criterion will be assessed through three binary questions (corresponding to the three constituent criteria) to be answered by the FET operator immediately after the procedure.

This is a combined criterion, requiring the validation of the following three criteria for the utilization of these headsets to be considered "feasible":

  • Availability of the headset on the day of the FET (yes/no)
  • Provision of the headset by the caregiver of the FET (yes/no)
  • Optimal use of the headset during the FET (yes/no) (i.e., optimal use is defined as the absence of technical incidents or battery depletion throughout the headset's usage duration during the procedure) A negative response to any of these three criteria will result in the procedure being deemed not feasible
The composite criterion will be assessed through three binary questions (corresponding to the three constituent criteria) to be answered by the FET operator immediately after the procedure.

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Duration of medical device usage (number of minutes)
Time Frame: This information will be collected by the FET operator immediately after FET.
The duration will be estimated by the difference between the time of setting up the medical device and the time of removing the headset.
This information will be collected by the FET operator immediately after FET.
Measurement of procedure acceptability from the patients' perspective
Time Frame: This information will be completed by the patient immediately after the FET.

It will be determined by the presence or absence of adverse effects experienced during the use of the device, collected through a binary question to which the patient will respond.

In case of a positive response, the adverse effects will then be described, based on a (non-exhaustive) list provided to the patient, along with a declarative item if the adverse effect is not present in the list.

This information will be completed by the patient immediately after the FET.
Satisfaction rate of patient regarding the procedure.
Time Frame: This information will be completed by the patient immediately after the FET.
The assessment of satisfaction related to the use of the VRH headset will be measured using a Likert scale (very satisfied/satisfied/no opinion/dissatisfied/very dissatisfied).
This information will be completed by the patient immediately after the FET.
Satisfaction rate of healthcare providers regarding the procedure.
Time Frame: This information will be completed by the caregiver immediately after the FET.
The assessment of satisfaction related to the use of the VRH headset will be measured using a Likert scale (very satisfied/satisfied/no opinion/dissatisfied/very dissatisfied).
This information will be completed by the caregiver immediately after the FET.
Effect of VRH headset usage on patient anxiety, measured through the change in average anxiety score
Time Frame: The 〖"STAI-Y1" 〗_"STATE " self-assessment anxiety questionnaire will be provided to the patient in paper format just before the FET and immediately after the procedure.
Comparison of the average anxiety score measured using the 〖"STAI-Y1" 〗_"STATE " , before and after device usage.
The 〖"STAI-Y1" 〗_"STATE " self-assessment anxiety questionnaire will be provided to the patient in paper format just before the FET and immediately after the procedure.
Rate of biological pregnancies obtained after the FETs
Time Frame: This information will be obtained by reviewing the electronic medical records of the patients 1 month after the FET.
The proportion of patients who have achieved a biological pregnancy will be determined by collecting the systematically performed HCG level measurement 10 days after the transfer.
This information will be obtained by reviewing the electronic medical records of the patients 1 month after the FET.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

December 13, 2023

Primary Completion (Actual)

May 24, 2024

Study Completion (Actual)

May 24, 2024

Study Registration Dates

First Submitted

August 21, 2023

First Submitted That Met QC Criteria

August 28, 2023

First Posted (Actual)

August 29, 2023

Study Record Updates

Last Update Posted (Actual)

June 10, 2024

Last Update Submitted That Met QC Criteria

June 7, 2024

Last Verified

June 1, 2024

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Anxiety

Clinical Trials on Use of virtual reality hypnosis headset during frozen embryo transfer

3
Subscribe